Beam Therapeutics Inc. Proceeds from Sale and Maturity of Held-to-maturity Securities
Beam Therapeutics Inc. (BEAM) reported Proceeds from Sale and Maturity of Held-to-maturity Securities of $20.45 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities · last filed 2021-05-11
- Beam Therapeutics Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2021-03-31 was $20.45M, a 54.27% decline year-over-year.
- Beam Therapeutics Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2020-12-31 was $41.22M, a 11.08% increase year-over-year.
- Beam Therapeutics Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2020-09-30 was $69.18M.
- Beam Therapeutics Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2020-06-30 was $43.48M.
- Beam Therapeutics Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2020 was $198.60M, a 161.07% increase from fiscal 2019.
- Beam Therapeutics Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2019 was $76.07M.
| Period end | Proceeds from Sale and Maturity of Held-to-maturity Securities 3 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 6 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 9 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2021-03-31 | $20.45M 10-Q · filed 2021-05-11 | $61.67M derived: sum of 2 quarters · filed 2021-05-11 | $130.85M derived: sum of 3 quarters · filed 2021-05-11 | $174.32M derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | $41.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $110.40M derived: sum of 2 quarters · filed 2021-03-15 | $153.87M derived: sum of 3 quarters · filed 2021-03-15 | $198.60M 10-K · filed 2021-03-15 |
| 2020-09-30 | $69.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $112.66M derived: sum of 2 quarters · filed 2020-11-10 | $157.38M 10-Q · filed 2020-11-10 | $194.49M derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-06-30 | $43.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $88.20M 10-Q · filed 2020-08-12 | $125.30M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2020-03-31 | $44.72M 10-Q · filed 2021-05-11 | $81.83M derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $37.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $76.07M 10-K · filed 2021-03-15 | ||
| 2019-09-30 | $38.96M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |